Dermira, Inc.

Basf Se Corporation

Salix Pharmaceuticals, Inc.

Ferrokin Biosciences, Inc.

Amri Ssci, LLC

Gilead Sciences, Inc.

Millennium Pharmaceuticals Limited

Cymabay Therapeutics, Inc.

Kronos Bio, Inc.

Journey Medical Corporation

Other

Nektar Therapeutics

Bial-portela Ca & S.a.

Metabolex, Inc.

Gi Therapeutics, Inc.

Patricia Andres

Jennifer Leigh Nelson

Lisa Lynn McQueen

Mark Andres

Anthony Adrian Shaw

Delphine Caroline Imbert

Stephan Xander Mattheus Boerrigter

John Allan Statler

Stephan D Parent

Jon Gordon Selbo

Ekaterina Albert

Jared Peters Smit

Brian Michael Green

Jason A Hanko

Stephen Craig Fields

Matthew Richard Oberholzer

Hugh Young Rienhoff, Jr

Amy E Tapper

Samir Kulkarni

Yiduo Wu

Paul Schields

Fei Ding

Huamin Zhang

Charles A McWherter

Jiangao Song

Jing Teng

Fang Ma

R Martin Emanuele

David Alexander Learmonth

Fang Wang

Petinka I Vlahova

Paul A Roethle

Melanie Janelle Bevill

Igor Ivanisevic

Duong D Tran

Chiajen Lai

Valeriya N Smolenskaya

Marianne Langston

Debra L Mazaik

Peter C Fung

Pierre Giguere

Tabitha Williford

Tanise Shattock-Gordon

Craig Stewart

Brian Yarmuch

Krista Marie Diaz

Iva Trantcheva

Alexander Smith

Mahmoud Mirmehrabi

Alexander Beliaev

Brandon Heath Brown

Hannah S White

Lei Zhu

Eric L Elliott

Christopher Scott Seadeek

Nicholas D Paschalides

Xufeng Sun

Richard James Ely

Brian Broadbelt

Anton Peterson

Lisa Mcqueen

Sarah Bethune

Yoo Joong Kim

Yogesh Datar

Ramakrishna Gadiraju

Bruce Andrew Kowalczyk

Gabriel Christian Kuklis

Charles A Mcwherter

Valeriya Smolenskaya

Paul Roethle

Stephan Xander Boerrigter

Lisa Lynn Mcqueen

Stephan Parent

Mark Christopher Andres

Solid forms of the compound, 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine, and solid forms of salts or co-crystals of Compound I, were prepared and characterized: Also provided are processes of making the solid forms and methods of use thereof.

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor

Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are described.

Methods for the purification of L-glufosinate

The present invention provides crystalline forms, solvates and hydrates of 4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one, and methods of making.

Solid forms of a toll-like receptor modulator

Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate. In some embodiments, a portion of the glutamate in the starting composition may be separated from the L-glufosinate using a crystallization step. Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are also described.

Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms. Cocrystals of cannabidiol and a coformer selected from L-proline, D-proline, tetramethylpyrazine, and 4,4'-dipyridyl are also disclosed herein.

Solid forms of cannabidiol and uses thereof

Solid forms of the compound, 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine, and solid forms of salts or co-crystals of Compound I, were prepared and characterized:  Also provided are processes of making the solid forms and methods of use thereof.

Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors

Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.

Glycopyrrolate salts

This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Morphic forms of G1T38 and methods of manufacture thereof

The present invention is directed to cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxcyclopentyl) methyl sulfamate of formula (I). The invention is also directed to methods of making cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate of formula (I). The invention is also directed to the pharmaceutical use of a cocrystal form as an E1 activating enzyme inhibitor, as well as a pharmaceutical composition comprising a cocrystal form. The invention is further directed to a method of treatment comprising administering a cocrystal form of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate of formula (I). 

Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof

Growing community of inventors

West Lafayette, IN, United States of America

Patricia Andres